login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
All US stocks
All Canadian stocks
All European stocks
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
BLUENERGIES LTD (BLU.CA) Stock News
TSX:BLU - Toronto Stock Exchange -
CA0959221007
-
Common Stock
- Currency: CAD
0.43
-0.01 (-2.27%)
Summary
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
BLU.CA Latest News, Press Relases and Analysis
All
Press Releases
2 years ago - By: BELLUS Health Inc.
- Mentions:
BLU
BELLUS Health Inc. Announces Voting Results from Special Meeting of Shareholders
2 years ago - By: BELLUS Health Inc.
- Mentions:
BLU
GSK
BELLUS Health Inc. Calls Special Shareholders’ Meeting in Connection with GSK Acquisition
2 years ago - By: BELLUS Health Inc.
- Mentions:
BLU
BELLUS Health Reports First Quarter 2023 Financial Results and Business Highlights
2 years ago - By: BELLUS Health Inc.
- Mentions:
BLU
BELLUS Health Announces Meeting Updates
2 years ago - By: BELLUS Health Inc.
- Mentions:
BLU
GSK
GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health
2 years ago - By: Bloomberg
GSK to Buy Bellus for $2 Billion to Gain Cough Medicine
2 years ago - By: BELLUS Health Inc.
- Mentions:
BLU
BELLUS Health Announces Positive Results from its Phase 1 Bioavailability Equivalence Study Evaluating Once-Daily Extended-Release Formulation of Camlipixant in Comparison to Twice-Daily Immediate Release Formulation
2 years ago - By: BELLUS Health Inc.
- Mentions:
BLU
BELLUS Health Reports Year 2022 Financial Results and Business Highlights
2 years ago - By: BELLUS Health Inc.
- Mentions:
BLU
BELLUS Health to Participate in the Cowen 43rd Annual Health Care Conference
2 years ago - By: BELLUS Health Inc.
- Mentions:
BLU
BELLUS Health to Present on the Patient Experience and the Burden of Refractory Chronic Cough at the American Academy of Allergy, Asthma & Immunology Annual Meeting
3 years ago - By: BELLUS Health Inc.
- Mentions:
BLU
BELLUS Health Reports Third Quarter 2022 Financial Results and Business Highlights
3 years ago - By: BELLUS Health Inc.
- Mentions:
BLU
BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences
3 years ago - By: BELLUS Health Inc.
- Mentions:
BLU
BELLUS Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937 at the CHEST Annual Meeting
3 years ago - By: BELLUS Health Inc.
- Mentions:
BLU
BELLUS Health to Present at the H.C. Wainwright Global Investment Conference
3 years ago - By: BELLUS Health Inc.
- Mentions:
BLU
BELLUS Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937 at the European Respiratory Society International Congress 2022
3 years ago - By: BELLUS Health Inc.
- Mentions:
BLU
BELLUS Health Reports Second Quarter 2022 Financial Results and Business Highlights
3 years ago - By: BELLUS Health Inc.
- Mentions:
BLU
BELLUS Health Closes US$153 Million Public Offering of Common Shares in Canada and the United States
3 years ago - By: BELLUS Health Inc.
- Mentions:
BLU
BELLUS Health Announces Pricing of US$153 Million Public Offering in Canada and the United States
3 years ago - By: BELLUS Health Inc.
- Mentions:
BLU
BELLUS Health Announces the Launch of a Public Offering of Common Shares in Canada and the United States
3 years ago - By: BELLUS Health Inc.
- Mentions:
BLU
Bellus Health Announces Positive End-of-Phase 2 Meeting with the FDA and its CALM Phase 3 Program for BLU-5937 in Refractory Chronic Cough
3 years ago - By: BELLUS Health Inc.
- Mentions:
BLU
BELLUS Health to Participate in the William Blair Biotech Focus Conference
3 years ago - By: BELLUS Health Inc.
- Mentions:
BLU
BELLUS Health to Participate in the Jefferies Healthcare Conference
3 years ago - By: BELLUS Health Inc.
- Mentions:
BLU
BELLUS Health Reports First Quarter 2022 Financial Results and Business Highlights
3 years ago - By: BELLUS Health Inc.
- Mentions:
BLU
BELLUS Health to Present Late-Breaking Clinical Data from the Phase 2b SOOTHE Trial of BLU-5937 at the ATS 2022 International Conference
3 years ago - By: BELLUS Health Inc.
- Mentions:
BLU
BELLUS Health to Participate in Multiple Upcoming Investor Conferences
3 years ago - By: BELLUS Health Inc.
- Mentions:
BLU
BELLUS Health Reports Year 2021 Financial Results and Business Highlights
4 years ago - By: BELLUS Health Inc.
- Mentions:
BLU
BELLUS Health Closes US$200 Million Public Offering of Common Shares in Canada and the United States
4 years ago - By: BELLUS Health Inc.
- Mentions:
BLU
BELLUS Health Announces Pricing of US$200 Million Public Offering in Canada and the United States
4 years ago - By: BELLUS Health Inc.
- Mentions:
BLU
BELLUS Health Announces the Launch of a Public Offering of Common Shares in Canada and the United States
4 years ago - By: BELLUS Health Inc.
- Mentions:
BLU
BELLUS Health Announces Positive Topline Results from its Phase 2b SOOTHE Trial of BLU-5937 for the Treatment of Refractory Chronic Cough
4 years ago - By: BELLUS Health Inc.
- Mentions:
BLU
BELLUS Health Reports Third Quarter 2021 Financial Results and Business Highlights
4 years ago - By: BELLUS Health Inc.
- Mentions:
BLU
BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences
4 years ago - By: BELLUS Health Inc.
- Mentions:
BLU
BELLUS Health Convenes Virtual Analyst Event to Discuss the Chronic Cough Landscape and its Selective P2X3 Antagonist BLU-5937
4 years ago - By: BELLUS Health Inc.
- Mentions:
BLU
BELLUS Health Announces Completion of Patient Enrollment in SOOTHE Phase 2b Trial for Refractory Chronic Cough and BLUEPRINT Phase 2a Trial for Chronic Pruritus Associated with Atopic Dermatitis
4 years ago - By: BELLUS Health Inc.
- Mentions:
BLU
BELLUS Health Announces Positive Interim Analysis from the Phase 2b SOOTHE Trial of BLU-5937 in Refractory Chronic Cough
4 years ago - By: BELLUS Health Inc.
- Mentions:
BLU
BELLUS Health to Present at the H.C. Wainwright Global Investment Conference
4 years ago - By: BELLUS Health Inc.
- Mentions:
BLU
BELLUS Health to Report Additional RELIEF Data in an Oral Presentation at the European Respiratory Society International Congress 2021
4 years ago - By: BELLUS Health Inc.
- Mentions:
BLU
BELLUS Health Reports Second Quarter 2021 Financial Results and Business Highlights
4 years ago - By: BELLUS Health Inc.
- Mentions:
BLU
BELLUS Health to Participate in the Jefferies Virtual Healthcare Conference
Please enable JavaScript to continue using this application.